Tianjin Pharmaceutical Da Ren Tang Group Unveils 2025 Action Plan Evaluation, Announces 2026 Strategic Initiatives

Key Highlights for Investors and Shareholders

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (“the Company”) has published an extensive evaluation of its 2025 Action Plan and outlined its strategic roadmap for 2026. These disclosures contain several important updates and initiatives that may have significant implications for investors and the Company’s future performance.

1. Strategic Focus and Business Refocusing

• Business Refocusing: In 2025, the Company completed the divestment of its pharmaceutical commercial segment, leading to a sharper focus on its core industrial business, especially Chinese patent medicines.
• Financial Performance: As a result of the divestment, the Company’s total operating revenue fell by 32.70% year-on-year to approximately RMB4.917 billion in FY2025. However, revenue from its core industrial segment grew by 8.64% year-on-year, reflecting robust growth in its principal business areas, particularly cardiovascular, cerebrovascular, and respiratory products.
• 2026 Outlook: The Company will focus on strengthening nine regional branches and key product lines, leveraging four major channels: medical institutions, retail, e-commerce, and direct-to-consumer. It aims to maintain steady growth through existing channels and drive new growth via innovative marketing, including a major public welfare campaign targeting cardiovascular emergency care awareness.

2. Enhancing Quality and Productivity

• Supply Chain & Quality Upgrades: Significant improvements were made in traceability, with 15 traceability bases established and 40% coverage of core raw materials. The Company created 46 internal standards for Chinese medicinal materials surpassing the Chinese Pharmacopoeia.
• Product Innovation: Age-friendly reforms were implemented for product packaging and instructions, including digital videos and audio functions for better accessibility. Safety information for 19 product instructions was scientifically updated and approved by regulators, while 14 products achieved international registration in Singapore.
• Digital Transformation and AI: The Company deepened its collaboration with Huawei Cloud, completed AI strategic planning, and received a unique digitalisation subsidy for its “Artificial Intelligence + Traditional Chinese Medicine Multi-scenario Application” project, making it the only pharmaceutical winner in this category.
• 2026 Initiatives: Plans include expanding traceability bases, increasing the use of fresh-cut raw materials, further upgrading the three-tier quality control system, and enhancing supply chain management and production flexibility.

3. Strong Commitment to Shareholder Returns

• Dividend Payouts: In July 2025, the Company distributed a cash dividend of RMB12.80 per 10 shares for FY2024, totaling RMB986 million. In February 2026, it paid out RMB24.50 per 10 shares for the first three quarters of FY2025, totaling RMB1.887 billion.
• Future Dividend Plans: The Company has formulated a 2026–2028 shareholder return plan and a profit distribution proposal for FY2025, both pending shareholder approval. It commits to prioritizing cash dividends where capital allows, in line with regulatory guidelines and CSRC initiatives.

4. Enhanced Transparency and Investor Relations

• Improved Disclosures: The Company has raised the readability of its announcements, expanded multi-dimensional disclosures (including ESG reports), and increased the use of visual aids.
• Active Engagement: Regular performance briefings, direct communication channels (including a dedicated “Chairman’s Mailbox”), and diverse investor activities—such as factory and museum tours, traditional medicine consultations, and health food tastings—have improved shareholder engagement and received positive feedback.
• 2026 Plans: Continued commitment to high-quality, transparent disclosures and regular investor communications.

5. Corporate Governance and Compliance Enhancements

• Governance Reform: Key changes in 2025 included abolishing the Supervisory Committee (with its functions transferred to the Audit Committee) and renaming the Strategy Committee to the Strategy and Sustainability Committee. A formal sustainability policy was also established.
• Upcoming Developments: In 2026, the Company will further refine the remuneration system for directors and senior management and continue to update its internal policies in alignment with regulatory standards.

6. Focused Oversight and Compliance for Key Personnel

• Training and Compliance: In 2025, key personnel participated in compliance training with major exchanges and associations. The Company issued Anti-monopoly Compliance Guidelines, launched a digital contract system, and achieved national-level certification for its marketing compliance management.
• Incentives and Oversight: In 2026, further improvements are planned for incentive and oversight mechanisms for key personnel, with continued compliance education.

7. Forward-Looking Statements and Investor Caution

• The Company cautions that strategic plans and forward-looking statements may be influenced by macroeconomic, policy, and industry factors and are subject to uncertainties. They do not constitute binding commitments or guarantees.

Potential Share Price Implications

• Positive: The robust growth in the industrial segment and strong dividend payouts may support share price appreciation. The focus on high-margin core products, successful digital and AI initiatives, and enhanced shareholder engagement signal management’s commitment to value creation and transparency.
• Watch Points: The decline in total revenue following the commercial segment divestment, and forward-looking uncertainties, could introduce volatility. Investors should monitor approval of new shareholder return plans and ongoing execution of AI/digital strategies for further share price catalysts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Forward-looking statements are subject to risks and uncertainties. Investors are advised to exercise caution and conduct their own due diligence before making investment decisions.

View TJ DaRenTang USD Historical chart here